ibudilast has been researched along with Alcoholism in 7 studies
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we examined the ability of ibudilast, a non-selective phosphodiesterase inhibitor, to reduce alcohol drinking and relapse in alcohol-preferring P rats, high-alcohol drinking HAD1 rats, and in mice made dependent on alcohol through cycles of alcohol vapor exposure." | 7.81 | Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. ( Becker, HC; Bell, RL; Cui, C; Egli, M; Franklin, KM; Johnson, KW; Lopez, MF, 2015) |
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 7.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by ∼50%." | 6.84 | Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. ( Bujarski, S; Heinzerling, K; Miotto, K; Ray, LA; Roche, DJ; Shoptaw, S, 2017) |
| " In this study, we examined the ability of ibudilast, a non-selective phosphodiesterase inhibitor, to reduce alcohol drinking and relapse in alcohol-preferring P rats, high-alcohol drinking HAD1 rats, and in mice made dependent on alcohol through cycles of alcohol vapor exposure." | 3.81 | Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. ( Becker, HC; Bell, RL; Cui, C; Egli, M; Franklin, KM; Johnson, KW; Lopez, MF, 2015) |
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 3.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "Non-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25)." | 3.01 | Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder. ( Burnette, EM; Grodin, EN; Irwin, MR; Ray, LA, 2021) |
| "Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by ∼50%." | 2.84 | Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. ( Bujarski, S; Heinzerling, K; Miotto, K; Ray, LA; Roche, DJ; Shoptaw, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Burnette, EM | 2 |
| Ray, LA | 6 |
| Irwin, MR | 3 |
| Grodin, EN | 5 |
| Nieto, SJ | 1 |
| Meredith, LR | 2 |
| Burnette, E | 2 |
| O'Neill, J | 1 |
| Alger, J | 1 |
| London, ED | 1 |
| Miotto, K | 4 |
| Evans, CJ | 1 |
| Green, R | 1 |
| Chorpita, M | 1 |
| Baskerville, WA | 1 |
| Bujarski, S | 2 |
| Towns, B | 1 |
| Nieto, S | 1 |
| Lim, A | 1 |
| Lin, J | 1 |
| Gillis, A | 1 |
| Evans, C | 1 |
| Bell, RL | 1 |
| Lopez, MF | 1 |
| Cui, C | 1 |
| Egli, M | 1 |
| Johnson, KW | 1 |
| Franklin, KM | 1 |
| Becker, HC | 1 |
| Shoptaw, S | 1 |
| Roche, DJ | 1 |
| Heinzerling, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder[NCT03489850] | Phase 2 | 52 participants (Actual) | Interventional | 2018-07-16 | Completed | ||
| Development of Ibudilast as a Novel Treatment for Alcohol Dependence[NCT02025998] | Phase 1 | 24 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder[NCT03594435] | Phase 2 | 102 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Medication effects on number of days where any drinking was reported. . Values indicate estimated probability of a drinking day across time for each group. (NCT03489850)
Timeframe: 14 days
| Intervention | predicted probability in percent (Number) |
|---|---|
| Ibudilast | 59.25 |
| Placebo | 63.63 |
Medication effects on number of heavy drinking days. Heavy drinking is defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as ≥5 drinks/day for men and ≥4 drinks/day for women. Values indicate estimated probability of a heavy drinking day across time for each group. (NCT03489850)
Timeframe: 14 days
| Intervention | predicted probability in percent (Number) |
|---|---|
| Ibudilast | 24.16 |
| Placebo | 36.80 |
"Negative affect as measured by self-reported ratings of Downhearted, Discouraged, Uneasy, and Anxious. Each item was rated on a scale from 0 (not at all) to 4 (extremely). The 4 items were summed for the total negative affect score for each day, ranging from 0 - 16. Higher scores indicate more negative mood." (NCT03489850)
Timeframe: Assessed through daily prompts throughout the 2-week study period.
| Intervention | units (Least Squares Mean) |
|---|---|
| Ibudilast | 2.91 |
| Placebo | 2.47 |
Medication effect on alcohol cue-induced ventral striatal activation. Participants completed an fMRI alcohol cue-reactivity paradigm where they viewed pictures of alcoholic beverages, non-alcoholic beverages, blurred images, and a plus sign. The mean percent signal change between the ALC and BEV blocks was extracted from an a priori defined region of interest: bilateral ventral striatum (VS), 6 mm-radius sphere centered at ±12 6 9 in MNI space. (NCT03489850)
Timeframe: Day 8
| Intervention | percent signal change (Mean) |
|---|---|
| Ibudilast | -0.08 |
| Placebo | 0.14 |
6 trials available for ibudilast and Alcoholism
| Article | Year |
|---|---|
Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder.
Topics: Adult; Alcoholism; Brain; Connectome; Female; Humans; Magnetic Resonance Imaging; Male; Phosphodiest | 2021 |
Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial.
Topics: Alcohol Drinking; Alcoholism; Animals; Aspartic Acid; C-Reactive Protein; Choline; Creatine; Humans; | 2022 |
Ibudilast moderates the effect of mood on alcohol craving during stress exposure.
Topics: Affect; Alcohol Drinking; Alcoholism; Craving; Ethanol; Humans; Indolizines; Pyrazoles; Pyridines | 2022 |
Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials, Phase II as Topic; Craving; Double-Blind Method; Fema | 2020 |
Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial.
Topics: Alcohol Drinking; Alcoholism; Craving; Cues; Humans; Magnetic Resonance Imaging; Pyridines | 2021 |
Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.
Topics: Adult; Affect; Alcohol Deterrents; Alcoholism; Central Nervous System Depressants; Craving; Cross-Ov | 2017 |
1 other study available for ibudilast and Alcoholism
| Article | Year |
|---|---|
Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Male; Mice; Phospho | 2015 |